AVIR stock forecast, quote, news & analysis
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases... Show more
Why Atea Pharmaceuticals (AVIR) Stock Is Down -16% in the Last 30 Days
Key Takeaways
- Atea Pharmaceuticals (AVIR) fell roughly 16% over the last 30 days, from a close of $5.33 on September 18, 2026 to about $4.48, despite positive Phase 3 hepatitis C data announced earlier in the quarter.
- The pullback followed a sharp, data-driven rally that carried shares to a peak near $5.83 in early September, pointing to profit-taking rather than a fundamental setback.
- Over the trailing three months, the stock is down roughly 8%, reflecting pronounced intra-period volatility in a clinical-stage, catalyst-dependent biotech.
- Atea's lead candidate, the bemnifosbuvir/ruzasvir (BEM/RZR) combination, met its Phase 3 primary endpoint in the C-BEYOND trial; a second pivotal readout (C-FORWARD) is expected in early 2027.
- With no near-term clinical catalyst until that second readout and third-quarter results due around November 11, sentiment has cooled during a catalyst gap.
Atea Pharmaceuticals (AVIR) Company Overview and Market Position
Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company headquartered in Boston, Massachusetts, focused on discovering and developing oral antiviral therapies for serious viral infections. Its lead program is a once-daily, fixed-dose combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, currently in Phase 3 development for the treatment of chronic hepatitis C virus (HCV) infection. The company is also advancing AT-587, a potential treatment for hepatitis E virus (HEV), for which no approved therapies currently exist.
Founded in 2012 and publicly listed on Nasdaq since 2020, Atea has no approved products or recurring revenue and operates with roughly 55 employees. Its market capitalization sits near $350 million, with cash, cash equivalents, and marketable securities of about $219.5 million as of June 30, 2026. Investors follow the stock primarily for binary clinical catalysts, particularly the HCV franchise's path toward regulatory filing.
Atea Pharmaceuticals (AVIR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AVIR declined approximately 16%, moving from a closing price of $5.33 on September 18, 2026 to about $4.48 in late-October trading. The decline was gradual rather than event-driven, with the stock drifting lower through late September and accelerating in mid-October before finding support near the $4.30 to $4.50 area.
The trailing three-month picture is more nuanced. From roughly $4.87 in late July, AVIR initially surged on positive Phase 3 data, climbing to an intraday peak near $5.90 and closing as high as $5.83 in early September. That advance, representing a gain of more than 15% from late-July levels, has since been fully retraced, leaving the stock down about 8% over the trailing quarter. The result is a round trip that underscores the stock's high sensitivity to news flow and sentiment.
What Drove AVIR Stock Price in the Last 30 Days
The 30-day decline appears to be driven by profit-taking and a period of reduced news flow rather than a single negative company-specific event. After the positive C-BEYOND Phase 3 readout in July and a better-than-expected second-quarter earnings report in August, the stock had run up significantly, creating room for investors to lock in gains as the initial enthusiasm faded.
A catalyst gap has also weighed on the shares. With the next major clinical milestone, the C-FORWARD topline result, not expected until early 2027, there is limited near-term fundamental news to sustain momentum. Technically, the stock slipped below its 50-day moving average near $5.26 and its 200-day average near $4.89, and its relative strength index moved into oversold territory, reflecting the breadth of the sell-off. Broader volatility in small-cap and clinical-stage biotechnology names has compounded the pressure.
What Drove AVIR Stock Performance Over the Last Quarter
The dominant driver of the quarter was clinical progress in the HCV program. In July 2026, Atea reported positive topline results from the C-BEYOND Phase 3 trial in North America, in which the BEM/RZR regimen met its primary endpoint of statistical non-inferiority to sofosbuvir/velpatasvir, sold by Gilead Sciences (GILD) as Epclusa. In the modified intent-to-treat population, BEM/RZR achieved a 93.9% sustained virologic response rate versus 94.8% for the comparator, while offering an eight-week treatment course for patients without cirrhosis compared with a 12-week standard of care.
That data, followed by second-quarter 2026 earnings on August 12 in which Atea reported a net loss per share of $0.41, narrower than the $0.56 consensus estimate, powered the stock's rally into early September. The positive readout positions the regimen for a potential regulatory submission, though a second pivotal study, C-FORWARD, conducted outside North America with more than 880 patients, must still report results. Competition from entrenched pan-genotypic therapies, including AbbVie (ABBV)'s Mavyret and Gilead's Epclusa, remains a key consideration for the commercial outlook.
Trending AI Robots
For investors and traders seeking a systematic approach to volatile names like Atea Pharmaceuticals, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are surfaced in this section. Each bot varies in its strategy, trading timeframe, and performance metrics, allowing users to compare approaches that suit different risk profiles and holding periods. Exploring the page can help market participants see how algorithmic strategies are currently positioning across sectors and individual stocks.
AVIR Stock Forecast Drivers: What Investors Should Watch Next
The most consequential near-term catalysts for Atea are clinical and regulatory. The C-FORWARD Phase 3 trial, which is fully enrolled with more than 880 patients across multiple HCV genotypes outside North America, is expected to report topline results in early 2027, and a positive outcome could support a potential new drug application submission later that year. Management has also indicated peak annual U.S. net revenue potential above $700 million for the regimen, subject to successful development and approval.
Beyond the HCV program, investors will monitor progress on AT-587 for hepatitis E virus, cash burn and runway, and the company's third-quarter 2026 financial results, scheduled for around November 11. Macroeconomic conditions, small-cap biotech sentiment, and competitive dynamics in the HCV market are additional factors that could influence the share price. A limited group of covering analysts maintains a consensus price target near $9.42, well above recent trading levels, though the small analyst base and binary clinical risks warrant caution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AVIR's RSI Indicator stays in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVIR advanced for three days, in 196 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
AVIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AVIR as a result. In 69 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
AVIR moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AVIR crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for AVIR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.587) is normal, around the industry mean (3.043). P/E Ratio (-1.942) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. AVIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of vaccines
Industry Biotechnology